Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission

References

• Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature. 1973;243(5405):290–293.
   PubMed Web of Science ®Google Scholar
• Ono T. Which tyrosine kinase inhibitors should be selected as the First-Line treatment for chronic myelogenous leukemia in chronic phase? Cancers. 2021;13(20):5116.
   PubMed Web of Science ®Google Scholar
• Medves S, Demoulin JB. Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. J Cell Mol Med. 2012;16(2):237–248.
   PubMed Web of Science ®Google Scholar
• Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172–183.
   PubMed Web of Science ®Google Scholar
• Ureshino H. Treatment-free remission and immunity in chronic myeloid leukemia. Int J Hematol. 2021;113(5):642–647.
   PubMedGoogle Scholar
• Efficace F, Cannella L. The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2016;2016(1):170–179.
   PubMedGoogle Scholar
• Padula WV, Larson RA, Dusetzina SB, et al. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. J Natl Cancer Inst. 2016;108(7)
   PubMedGoogle Scholar
• Roma S, Carpen L, Raveane A, et al. The dual role of innate lymphoid and natural killer cells in cancer. from phenotype to Single-Cell transcriptomics, functions and clinical uses. Cancers. 2021;13(20):5042.
   PubMedGoogle Scholar
• Jang H, Kim EH, Chi SG, et al. Nanoparticles targeting innate immune cells in tumor microenvironment. Int J Mol Sci. 2021;22(18)
   Google Scholar
• Carlsten M, Järås M. Natural killer cells in myeloid malignancies: Immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells. Front Immunol. 2019;10:2357.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633–640.
   PubMed Web of Science ®Google Scholar
• Pierson BA, Miller JS. CD56 + bright and CD56 + dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood. 1996;88(6):2279–2287.
   PubMed Web of Science ®Google Scholar
• Ilander M, Olsson-Strömberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31(5):1108–1116.
   PubMed Web of Science ®Google Scholar
• Chen CI, Koschmieder S, Kerstiens L, et al. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia. 2012;26(3):465–474.
   PubMedGoogle Scholar
• Kaweme NM, Zhou F. Optimizing NK cell-based immunotherapy in myeloid leukemia: abrogating an immunosuppressive microenvironment. Front Immunol. 2021;12(683381):683381.
   PubMedGoogle Scholar
• Kong J, Qin YZ, Zhao XS, et al. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment. Ann Hematol. 2021;100(10):2557–2566. Oct
   PubMedGoogle Scholar
• Xu H, Jia J. Single-Cell RNA sequencing of peripheral blood reveals immune cell signatures in alzheimer's disease. Front Immunol. 2021;12(645666):645666.
   PubMedGoogle Scholar
• Xiong LL, Xue LL, Du RL, et al. Single-cell RNA sequencing reveals B cell-related molecular biomarkers for Alzheimer's disease. Exp Mol Med. 2021;53(12):1888–1901. Dec
   PubMedGoogle Scholar
• Li XY, Shen Y, Zhang L, et al. Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing. Biochim Biophys Acta Rev Cancer. 2022;1877(3):188720.
   PubMedGoogle Scholar
• Zaongo SD, Harypursat V, Chen Y. Single-Cell sequencing facilitates elucidation of HIV immunopathogenesis: a review of current literature. Front Immunol. 2022;13:828860.
   PubMedGoogle Scholar
• Fan Y, Zhou H, Liu X, et al. Applications of Single-Cell RNA sequencing in cardiovascular research. Front Cell Dev Biol. 2021;9(810232):810232.
   PubMedGoogle Scholar
• Yoon SR, Lee YS, Yang SH, et al. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant. 2010;45(6):1038–1046.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28(6):955–959.
   PubMed Web of Science ®Google Scholar
• Stojanovic A, Correia MP, Cerwenka A. Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron. 2013;6(2):135–146.
   PubMedGoogle Scholar
• Fei F, Lim M, George AA, et al. Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells. Leukemia. 2015;29(4):788–797. Apr
   PubMedGoogle Scholar
• Nguyen A, Khoo WH, Moran I, et al. Single cell RNA sequencing of rare immune cell populations. Front Immunol. 2018;9(1553)
   Google Scholar
• Lee BJ, Mace EM. From stem cell to immune effector: how adhesion, migration, and polarity shape T-cell and natural killer cell lymphocyte development in vitro and in vivo. Mol Biol Cell. 2020;31(10):981–991.
   PubMedGoogle Scholar
• Chang J, Liu L, Wang Y, et al. Investigating the multitarget mechanism of traditional chinese medicine prescription for Cancer-Related pain by using network pharmacology and molecular docking approach. Evid Based Complement Alternat Med. 2020;2020:7617261.
   PubMedGoogle Scholar
• Alali Z, Graham A, Swan K, et al. 60S acidic ribosomal protein P1 (RPLP1) is elevated in human endometriotic tissue and in a murine model of endometriosis and is essential for endometriotic epithelial cell survival in vitro. Mol Hum Reprod. 2020;26(1):53–64.
   PubMedGoogle Scholar
• Zhou C, Sun J, Zheng Z, et al. High RPS11 level in hepatocellular carcinoma associates with poor prognosis after curative resection. Ann Transl Med. 2020;8(7):466.
   PubMedGoogle Scholar
• Zhou C, Liu C, Liu W, et al. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway. Theranostics. 2020;10(10):4627–4643.
   PubMed Web of Science ®Google Scholar
• Lee H, Kim HS, Lee JM, et al. Natural killer cell function tests by Flowcytometry-Based cytotoxicity and IFN-γ production for the diagnosis of adult hemophagocytic lymphohistiocytosis. Int J Mol Sci. 2019;20(21)
   Google Scholar
• Giannopoulos K, Karczmarczyk A, Karp M, et al. In vivo, ex vivo and in vitro dasatinib activity in chronic lymphocytic leukemia. Oncol Lett. 2021;21(4):285.
   PubMedGoogle Scholar
• Sips M, Liu Q, Draghi M, et al. HLA-C levels impact natural killer cell subset distribution and function. Hum Immunol. 2016;77(12):1147–1153.
   PubMedGoogle Scholar
• Hamann I, Unterwalder N, Cardona AE, et al. Analyses of phenotypic and functional characteristics of CX3CR1-expressing natural killer cells. Immunology. 2011;133(1):62–73.
   PubMedGoogle Scholar
• Chen EB, Zhou ZJ, Xiao K, et al. The miR-561-5p/CX3CL1 signaling axis regulates pulmonary metastasis in hepatocellular carcinoma involving CX3CR1+ natural killer cells infiltration. Theranostics. 2019;9(16):4779–4794.
   PubMed Web of Science ®Google Scholar
• Grauwet K, Vitale M, De Pelsmaeker S, et al. Pseudorabies virus US3 protein kinase protects infected cells from NK Cell-Mediated lysis via increased binding of the inhibitory NK cell receptor CD300a. J Virol. 2016;90(3):1522–1533.
   PubMedGoogle Scholar
• Kim DO, Byun JE, Kim WS, et al. TXNIP regulates natural killer Cell-Mediated innate immunity by inhibiting IFN-γ production during bacterial infection. Int J Mol Sci. 2020;21(24)
   Google Scholar
• Vitallé J, Terrén I, Orrantia A, et al. CD300a inhibits CD16-mediated NK cell effector functions in HIV-1-infected patients. Cell Mol Immunol. 2019;16(12):940–942.
   PubMedGoogle Scholar
• Lankry D, Rovis TL, Jonjic S, et al. The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cells. Eur J Immunol. 2013;43(8):2151–2161.
   PubMedGoogle Scholar
• Lankry D, Simic H, Klieger Y, et al. Expression and function of CD300 in NK cells. J Immunol. 2010;185(5):2877–2886.
   PubMedGoogle Scholar
• Shi T, Xie M, Chen L, et al. Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult philadelphia-positive acute lymphoblastic leukemia in the TKI era. Exp Hematol Oncol. 2022;11(1):13.
   PubMedGoogle Scholar
• Shapiro RM, Birch GC, Hu G, et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for post-transplant relapse. J Clin Invest. 2022;e154334.
   PubMedGoogle Scholar